HematologyNews.net

Hematology Xagena

Xagena Mappa
Medical Meeting
Dermabase.it
Onco News

Search results for "Thrombocytopenia"

A phase II study, led by Andre Goy, of the University of Texas M.D. Anderson Cancer Center, Houston, evaluated efficacy and toxicity of Bortezomib ( Velcade ) in 60 patients with relapsed or refractor ...


The FDA ( Food and Drug Administration ) approved a supplemental New Drug Application ( sNDA ) for Velcade ( Bortezomib ). This approval expands the label to include the treatment of patients with m ...


Initial clinical results from Pivotal Phase III Special Protocol Assessment ( SPA ) trials using Revlimid ( Lenalidomide ) as a new approach in the treatment of heavily pretreated patients with relaps ...


A multicenter Phase II trial, MDS-002, showed that Revlimid ( Lenalidomide ) is active in a larger group of patients with low and intermediate-1 risk myelodysplastic syndromes ( MDS ), who lack a dist ...


Two phase II studies with Bortezomib ( Velcade ) showed very high response rates in front-line multiple myeloma. Overall response rates ranged from 88 to 95 percent with complete and near complete r ...


Interim data from a Phase 2 study evaluating the use of 500 mcg of Aranesp ( Darbepoetin alfa ) administered every three weeks to treat anemia in patients with a bone marrow disorder known as myelodys ...


A pivotal Phase IIb open-label study evaluated Vorinostat ( Zolinza ) in patients with advanced, refractory cutaneous T-cell lymphoma ( CTCL ). In the study, 30 percent of the patients ( 22 of 74 ) ...


A subset analysis of the international phase III trial ( AZA-001 ) has demonstrated that the overall survival benefit observed in higher-risk myelodysplastic syndromes ( MDS ) patients extended to pat ...


Four studies that highlight significant advances in treatment and survival outcomes for patients with various forms of thrombocytopenia, a group of bleeding disorders characterized by a low number of ...


Novel treatments have shown improvements in survival and response rates for leukemia and lymphoma. The use of Dexamethasone early in the treatment of children with acute lymphoblastic leukemia, the ...


Four studies that highlight significant advances in treatment and survival outcomes for patients with various forms of thrombocytopenia, a group of bleeding disorders characterized by a low number of ...


Novartis has informed Healthcare Professional on the safety of Exjade ( Deferasirox ), which is indicated for the treatment of chronic iron overload due to frequent blood transfusions, or when Desfera ...


A subset analysis of the international phase III trial ( AZA-001 ) has demonstrated that the overall survival benefit observed in higher-risk myelodysplastic syndromes ( MDS ) patients extended to pat ...


Patients suffering from a blood disorder that prevents proper clotting have the option of a new medication that may dramatically improve their health. There are estimated to be between 50,000 and 100, ...


New data from two long-term studies ( RAISE: 197 patients and EXTEND: 144 patients ) have shown that patients with idiopathic thrombocytopenic purpura ( ITP ), treated with Eltrombopag ( Revolade ), e ...